PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
复制标题
DOI：
10.3410/b2-10
复制
发表时间：
2010-02-11
期刊：
影响因子：
--
通讯作者：
Bates, Susan E
中科院分区：
文献类型：
--
作者：
Annunziata, Christina M;Bates, Susan E
BRCA and poly-ADP ribose polymerase (PARP) regulate pathways of DNA repair. Due to the accumulation of mutations introduced by error-prone DNA repair, breast and ovarian cancers develop in the setting of BRCA deficiency. A series of recent clinical trials has tested the use of PARP inhibition as a therapeutic strategy to target BRCA-deficient tumors.
